Association of Sleep Quality and Mental Status With Early Recurrence and Prognosis of Colorectal Cancer
Launched by MA YANLEI · May 30, 2024
Trial Information
Current as of February 14, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
Evidence of evidence-based medicine shows that patients with malignant tumors have heavy psychological pressure after disease, and are prone to different degrees of sleep disorders and mental health problems, which often affect the progression and prognosis of the primary tumor. Previous studies have reported that baseline sleep quality was independently associated with risk of progression, risk of death, and response to treatment in patients with metastatic colorectal cancer before and during chemotherapy. Surgery, as a stressor, often causes obvious psychological stress reactions in patie...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Preoperative fibrocolonoscopy and pathological examination confirmed colorectal cancer;
- • 2. Age 18 \~ 80 years old;
- • 3. Baseline clinical stage TNM Ⅰ to Ⅲ : cT1-4N0-2M0 (AJCC-8 version);
- • 4. The United States Eastern Oncology Consortium (ECOG) physical status score was 0 to 2 points;
- • 5. Laboratory examination results before admission met the following surgical conditions: neutrophil (ANC) ≥1.5×109/L, platelets (PLT) ≥ 100×109/L, total bilirubin (TBI) ≤1.5× upper limit of normal (2mg/dl), alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤2× upper limit of normal; Coagulation parameters in the normal range;
- • 6. Able to complete the required research questionnaire independently or with the assistance of the researcher;
- • 7. Patients were willing to undergo regular follow-up after surgery and had no psychological, family, social, or geographic constraints that affected protocol compliance and follow-up time;
- • 8. Patients and their families can understand and are willing to participate in this clinical study, and sign informed consent.
- Exclusion Criteria:
- • 1. Under 18 years of age or over 80 years of age;
- • 2. Have a family history of severe mental illness;
- • 3. People with mental illness or intellectual disability who cannot correctly describe their feelings;
- • 4. The patient has severe systemic infection;
- • 5. No radical operation was performed during the operation due to various reasons;
- • 6. Patients with intestinal obstruction, intestinal perforation, intestinal bleeding, peritonitis, etc. requiring emergency surgery;
- • 7. Merge other parts of the transfer;
- • 8. Have serious heart, lung, liver and kidney diseases, can not tolerate surgery;
- • 9. Active stage of liver disease or abnormal liver function, ALT, AST, TBIL is more than 2 times the upper limit of normal value;
- • 10. Renal function damage, Cr ≥ 2 times the upper limit of normal value or BUN ≥ 2 times the upper limit of normal value;
- • 11. The subject's blood white blood cells are lower than the lower limit of normal, or platelets are lower than the lower limit of normal, or there are other blood system diseases;
- • 12. Severe coagulation mechanism disorder and bleeding tendency;
- • 13. Serious uncontrolled medical disease, recent history of myocardial infarction (within 3 months); Acute infection;
- • 14. Patients with uncontrolled severe hypertension and severe diabetes after intervention;
- • 15. The researchers considered that other candidates were not suitable for inclusion in this study.
Trial Officials
Yanlei Ma, PhD
Principal Investigator
Fudan University
About Ma Yanlei
Ma Yanlei is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodologies and ethical standards, Ma Yanlei collaborates with leading healthcare professionals and institutions to design and conduct high-quality clinical trials. The organization emphasizes transparency, compliance, and patient safety, striving to contribute valuable insights to the medical community and facilitate the development of groundbreaking treatments across various therapeutic areas.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Shanghai, Shanghai, China
Shanghai, , China
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0